Day One Biopharmaceuticals, Inc.
DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. Thā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.73
Price+8.23%
$0.74
1Y
Price
Market Cap
$999.033m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-103.1%
EBITDA Margin-89.4%
Net Profit Margin-62.8%
Free Cash Flow MarginRevenue
$187.638m
+43.1%
1y CAGR+14.4%
3y CAGR+10.8%
5y CAGREarnings
-$94.995m
+0.5%
1y CAGR+2.4%
3y CAGR-20.1%
5y CAGREPS
-$0.96
+5.9%
1y CAGR+15.2%
3y CAGR-7.9%
5y CAGRBook Value
$460.834m
$519.037m
Assets$58.203m
Liabilities$3.003m
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
-$120.521m
-50.1%
1y CAGR-13.4%
3y CAGR-33.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company